Država: Združene države Amerike
Jezik: angleščina
Source: NLM (National Library of Medicine)
POLYSULFATED GLYCOSAMINOGLYCAN (UNII: 268AW7000T) (POLYSULFATED GLYCOSAMINOGLYCAN - UNII:268AW7000T)
American Regent, Inc.
INTRAMUSCULAR
PRESCRIPTION
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints. Do not use in dogs showing hypersensitivity to PSGAG. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders.
Adequan® Canine Solution 100 mg/mL in a 5 mL preserved multiple dose vial. NDC 10797-975-02 5 mL Multiple Dose Vials Packaged 2 vials per box AMERICAN REGENT, INC. ANIMAL HEALTH Shirley, NY 11967 (1-888-354-4857) Approved by FDA under NADA # 141-038 Made in U.S.A. Rev. 9/2021 IN975 MG #44454
New Animal Drug Application
ADEQUAN CANINE- POLYSULFATED GLYCOSAMINOGLYCAN INJECTION, SOLUTION AMERICAN REGENT, INC. ---------- ADEQUAN CANINE polysulfated glycosaminoglycan Solution 100 mg/mL in a 5 mL preserved Multiple dose vial for intramuscular use in dogs. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION: The active ingredient in Adequan® Canine is polysulfated glycosaminoglycan (PSGAG). Polysulfated glycosaminoglycan is a semi-synthetic glycosaminoglycan prepared by extracting glycosaminoglycans (GAGs) from bovine tracheal cartilage. GAGs are polysaccharides composed of repeating disaccharide units. The GAG present in PSGAG is principally chondroitin sulfate containing 3 to 4 sulfate esters per disaccharide unit. The molecular weight for PSGAG used in the manufacture of Adequan® is 3,000 to 15,000 daltons. Each mL of Adequan® Canine contains 100 mg of PSGAG, 0.9% v/v benzyl alcohol as a preservative, and water for injection q.s. to 1 mL. Sodium hydroxide and/or hydrochloric acid added when necessary to adjust pH. The solution is clear, colorless to slightly yellow. PHARMACOLOGY: The specific mechanism of action of Adequan® in canine joints is not known. PSGAG is characterized as a “disease modifying osteoarthritis drug”. Experiments conducted _in_ _vitro_ have shown PSGAG to inhibit certain catabolic enzymes which have increased activity in inflamed joints, and to enhance the activity of some anabolic enzymes. For example, PSGAG has been shown to significantly inhibit serine proteinases. Serine proteinases have been demonstrated to play a role in the Interleukin-l mediated degradation of cartilage proteoglycans and collagen. PSGAG is reported to be an inhibitor of Prostaglandin E2 (PGE2) synthesis. PGE2 has been shown to increase the loss of proteoglycan from cartilage. PSGAG has been reported to inhibit some catabolic enzymes such as elastase, stromelysin, metalloproteases, cathepsin B1, and hyaluronidases, which degrade collagen, proteoglycans, and hyaluronic acid in Preberite celoten dokument